221 related articles for article (PubMed ID: 37978195)
41. High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry.
Marino F; Chong C; Michaux J; Bassani-Sternberg M
Methods Mol Biol; 2019; 1913():67-79. PubMed ID: 30666599
[TBL] [Abstract][Full Text] [Related]
42. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
[TBL] [Abstract][Full Text] [Related]
43. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
[TBL] [Abstract][Full Text] [Related]
44. Immunopeptidomics toolkit library (IPTK): a python-based modular toolbox for analyzing immunopeptidomics data.
ElAbd H; Degenhardt F; Koudelka T; Kamps AK; Tholey A; Bacher P; Lenz TL; Franke A; Wendorff M
BMC Bioinformatics; 2021 Aug; 22(1):405. PubMed ID: 34404349
[TBL] [Abstract][Full Text] [Related]
45. Identification of the Cryptic HLA-I Immunopeptidome.
Erhard F; Dölken L; Schilling B; Schlosser A
Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
[TBL] [Abstract][Full Text] [Related]
46. Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.
Hofmann S; Glückmann M; Kausche S; Schmidt A; Corvey C; Lichtenfels R; Huber C; Albrecht C; Karas M; Herr W
Mol Cell Proteomics; 2005 Dec; 4(12):1888-97. PubMed ID: 16112985
[TBL] [Abstract][Full Text] [Related]
47. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
48. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
49. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
[TBL] [Abstract][Full Text] [Related]
50. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
Front Immunol; 2020; 11():1981. PubMed ID: 32983136
[TBL] [Abstract][Full Text] [Related]
51. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
[TBL] [Abstract][Full Text] [Related]
52. Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.
Ebrahimi-Nik H; Michaux J; Corwin WL; Keller GL; Shcheglova T; Pak H; Coukos G; Baker BM; Mandoiu II; Bassani-Sternberg M; Srivastava PK
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219806
[TBL] [Abstract][Full Text] [Related]
53. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
[TBL] [Abstract][Full Text] [Related]
54. The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies.
Becker JP; Riemer AB
Front Immunol; 2022; 13():883989. PubMed ID: 35464395
[TBL] [Abstract][Full Text] [Related]
55. Purification and Identification of Naturally Presented MHC Class I and II Ligands.
Nelde A; Kowalewski DJ; Stevanović S
Methods Mol Biol; 2019; 1988():123-136. PubMed ID: 31147937
[TBL] [Abstract][Full Text] [Related]
56. Proteogenomics: advances in cancer antigen research.
Kanaseki T; Torigoe T
Immunol Med; 2019 Jun; 42(2):65-70. PubMed ID: 31318319
[TBL] [Abstract][Full Text] [Related]
57. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
58. The interdependence of machine learning and LC-MS approaches for an unbiased understanding of the cellular immunopeptidome.
Nielsen M; Ternette N; Barra C
Expert Rev Proteomics; 2022 Feb; 19(2):77-88. PubMed ID: 35390265
[TBL] [Abstract][Full Text] [Related]
59. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
60. In Immunopeptidomics We Need a Sniper Instead of a Shotgun.
Faridi P; Purcell AW; Croft NP
Proteomics; 2018 Jun; 18(12):e1700464. PubMed ID: 29377634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
